Experts, industry groups and patient advocates are closely watching the next steps in the Biden administration’s fledgling program to negotiate Medicare prices for high-cost drugs after all the selected drugmakers signed on to participate.
On Sept. 29, a Donald Trump-appointed judge in Ohio declined to halt the program. But the decision was preliminary, and the administration will have to survive at least nine lawsuits seeking to shut down the process. Experts are also watching for what information leaks from negotiations when they kick off early next year.
Many industry and legal experts are skeptical of the drugmakers’ legal claims. But Robin Feldman, a law professor with University of California College of the Law, San Francisco, said the battle’s ultimate fate is uncertain.
